A meta analysis on the utility of Anakinra in severe COVID-19 disease

Faculty of Medicine

Assiut University

A meta analysis on the utility of Anakinra in severe COVID-19 disease

Research Authors
Aliae AR Mohamed Hussein, Reem Sayad, Abdelrahman Abdelshafi, Islam Abdelaal Hammam, Ahmed M Kedwany, Shrouk Alaa-eldein Elkholy, Islam H Ibrahim
Research Date
Research Department
Department of Chest Diseases
Research Journal
Cytokine
Research Member
Aliae Abd Rabou Mohamed Hussein
Research Publisher
Academic Press
Research Vol
169
Research Website
https://doi.org/10.1016/j.cyto.2023.156311
Research Year
2023
Research Abstract

Background and objective

The most important presentation of COVID-19 is hyper inflammatory condition and cytokine storm that occurs due to excessive increase of the inflammatory mediators specially, pro-inflammatory interleukins such as IL-1β, IL-6 and tumor necrosis factor-α which have an important role in the cytokine storm pathway. Up till now there is not a definitive treatment for COVID-19 disease, but according to the pathophysiology of the disease, Anakinra (Interleukin- 1 inhibitor) is an adjuvant treatment option in patients with severe COVID-19 by blocking the effect of IL-1. So, we aimed to summarize the studies that evaluated the safety and efficacy of Anakinra in patients diagnosed with COVID-19.

Methods

We performed a search in PubMed, Cochrane Library, Scopus, and Web of Science (WOS) databases from inception till 7 Jan 2022. Additionally, we searched randomized and non-randomized